Osiris Therapeutics (OSIR) 5.00 $OSIR IMPORTANT

New Post Public Reply Private Reply Replies (0) Message Board

Jun 10, 2016 at 2:24 PM

Osiris Therapeutics (OSIR) 5.00 $OSIR

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc. and Advises Investors to Contact the Firm
BusinessWire - Thu Jun 02, 11:49AM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(Nasdaq: OSIR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
OSIR: 5.00 (unch)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"

(NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 5.00 (unch), MDXG: 7.88 (-0.10)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
PR Newswire - Wed Jun 01, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at
OSIR: 5.00 (unch)

INVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Tue May 31, 1:28PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NASDAQ: OSIR) concerning the Company and its officers' possible violations of federal securities laws.
OSIR: 5.00 (unch)

MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.00 (unch), MDXG: 7.88 (-0.10)

Osiris Provides Update Regarding NASDAQ Listing Matters
BusinessWire - Mon May 16, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"

, today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ"

.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Osiris to Present at the 26th European Wound Management Association Conference
BusinessWire - Tue May 10, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26th European Wound Management Association Conference.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in "Real World" Study
BusinessWire - Mon May 02, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix(R) versus EpiFix(R).
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Osiris to Present 15 Advanced Clinical and Scientific Abstracts
BusinessWire - Tue Apr 12, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring Conference, the nation's largest interdisciplinary wound care event within the clinical field.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Osiris Announces Further Expansion of Grafix Commercial Coverage
BusinessWire - Fri Apr 08, 11:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that over 52 million commercial beneficiaries are covered for Grafix(R).
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Osiris Therapeutics Announces Receipt of Deficiency Letter from NASDAQ
BusinessWire - Tue Mar 22, 3:30PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has received a letter from The NASDAQ Stock Market ("NASDAQ"

notifying the Company that it is not in compliance with NASDAQ Listing Rule 5250 (c)(1) because its Annual Report on Form 10-K for the year ended December 31, 2015 was not filed on a timely basis with the Securities and Exchange Commission.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Osiris Therapeutics Has Returned 66.5% Since SmarTrend Recommendation (OSIR)
Comtex SmarTrend(R) - Mon Mar 21, 1:05PM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 6 months, Osiris Therapeutics has returned 66.52% as of today's recent price of $5.62.
OSIR: 5.00 (unch)

Osiris Therapeutics to Present at the 4th Annual Cell and Gene Therapy Investor Day
BusinessWire - Fri Mar 18, 8:30AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Dwayne Montgomery, President and Chief Executive Officer, and Greg Law, Chief Financial Officer are scheduled to present at the Alliance for Regenerative Medicine's 4th Annual Cell and Gene Therapy Investor Day on Tuesday, March 22, 2016 at 10:00 a.m. ET in New York City.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Osiris Provides an Update on a Clinical Review by Blue Cross Blue Shield Association
BusinessWire - Wed Mar 16, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the Blue Cross Blue Shield Association has provided a positive review on Grafix(R) usage for individuals with diabetic lower-extremity ulcers.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Faruqi & Faruqi, LLP is Investigating Osiris Therapeutics, Inc. (OSIR) on Behalf of its Shareholders
PR Newswire - Wed Mar 16, 2:32PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NASDAQ:OSIR).
OSIR: 5.00 (unch)

Osiris Therapeutics Has Returned 55.9% Since SmarTrend Recommendation (OSIR)
Comtex SmarTrend(R) - Fri Mar 04, 4:33PM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 5 months, Osiris Therapeutics has returned 55.91% as of today's recent price of $7.40.
OSIR: 5.00 (unch)

Grafix Demonstrates Positive Clinical Outcomes in Chronic Complex Wounds with Exposed Tendon and Bone
BusinessWire - Fri Mar 04, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today the results of its prospective, multi-center, single-arm clinical trial evaluating the clinical outcomes of Grafix(R) in patients with complex chronic diabetic foot ulcers with exposed tendon and bone.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Osiris Confirms Dwayne Montgomery, as President and Chief Executive Officer, and the Election of Thomas M. Brandt to the Board of Directors
BusinessWire - Thu Mar 03, 3:00PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce that its Board of Directors, at a Board Meeting on March 3rd, 2016, confirmed the appointment of Dwayne Montgomery as the President and Chief Executive Officer. He will also serve as a Director of the company and stand for re-election by the company's Stockholders at its 2016 Annual Meeting.
OSIR: 5.00 (unch), SYK: 113.99 (-1.34)

Shares of OSIR Down 56.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 19, 9:21AM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 5 months, Osiris Therapeutics has returned 56.81% as of today's recent price of $7.25.
OSIR: 5.00 (unch)

Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 11.15 (-0.27), OSIR: 5.00 (unch), LGND: 114.13 (-0.95), ANIK: 49.12 (+0.20)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...